Author/Year | Comorbidity | M | Diabetes remission rate | R/C | Major outcomes | Major Complications | Follow-up |
---|---|---|---|---|---|---|---|
Du 2016 [23] | Hypertension, Dyslipidemia Hyperuricemia Sleep apnea | 0 | LRYGB/LSG: 75%/78.9% at 1-year; 57.4% /52.9% at 3-year. | 0 | BMI, FPG, 2 h-PG, HbA1C, FCP, 2 h-CP, FINS, HOMA-IR | one Incomplete intestinal obstruction, one mild upper gastrointestinal bleeding | All completed 1 year follow-up, 3 were lost at 2 years, 2 lost at 3 years. |
Di 2016 [24] | Hypertension, hyperlipidemia | 0 | 74.2% (49/66) at 1-year; 57.6% (38/66) at 3-year | 0 | BMI, FPG, 2 hPG, HbA1C, FCP, FINS, HOMA-IR | No state | All completed 3 years follow-up |
Gong 2016 [25] | Hypertriglyceridemia, Hypertension, Retinopathy Peripheral neuropathy | 0 | 93.5% (29/31) at 6-month | 0 | BMI, FPG, HbA1c, CP, FINS, GLP-1 | No severe complications | All completed at 1, 3 and 6 months follow-up |
Kular 2016 [26] | No state | 0 | 1, 2, 5 and 7 years were 81.8% (18/22), 78.9% (30/38),70.3% (57/81) and 68.5% (74/108) | 0 | BMI, waist, HbA1c, EWL, mean weight | excessive postoperative suture line bleeding with shock, anastomotic ulceration, anemia, low albumin, bile reflux, excess weight loss | Only 16%(128) of patients lost to follow0up after 7 years |
Li 2016 [27] | No state | 0 | 59.6% (34/57) at 1-year | 0 | FPG, 2hPBG, HbA1C, BMI, 1 h C-P | one early hemorrhage | All at 1 year follow-up |
Yang 2015 [28] | Hypertension | 0 | SG/RYGB: 78.6% (22/32)/ 85.2% (23/32) at 3-year | 0 | HbA1c, FBG, CP, BMI | Two gastroesophageal reflux, a anemia | 55 patient completed 3 years follow-up |
Yi 2015 [29] | No state | 0 | LRYGB/LRYGBS: 30% (9/30)/47% (14/30) | 0 | BMI, HOMA-IR, HbA1c, FPG, FCP, 2hCP | 10 marginal ulcers, two gastrointestinal hemorrhage | All at 1 year follow-up |
Kim 2014 [30] | No state | 0 | 53%, 63%, 90% at 1, 2 and 3 year | 1a | BMI, HbA1c, Fasting glucose, 2 h glucose, CP, Insulin, HOMA-IR | Postoperative bleeding, outflow stasis, infected fluid collection, leakage | 144 at 1 year; 116 at 2 year, 51 at 3 year |
Shrestha 2013 [31] | No state | 0 | A significant decrease in the levels of FPG, 2 h PG, HbA1c, and TG | 0 | BMI, HbA1c, FPG, 2hPG, FINS, HOMA-IR | No state | All at 3 month follow-up |
Lakdawala 2013 [32] | Hypertension, dyslipidemia, hyperuricemia, gastroesophageal reflux disease, sleep apnea, joint pain | 0 | 96.2% (50/52) at 1 year and 5 year | 0 | Average blood glucose, FINS, postprandial serum insulin, FCP, HbA1c | one seromas and one nausea, no major complication | 4d, 1,3,6, months, 1, 2, 3, 4, 5 years |
Wu 2013 [33] | No state | 0 | 75% at 2 months, 83.3% at 4 months | 0 | BMI, FPG, 2hPG, HbA1c | two vomiting and diarrhea, two gastric fistula and infection | All at 2 months, 6 at 4 months. |
Zhu 2012 [34] | Chronic gastritis, fatty liver, hypertension, hypertriglyceridemia, diabetic retinopathy, diabetic nephropathy | 0 | Significant reduction in Glycosylated hemoglobin, diabetes was completely resolved in 9 cases | 0 | BMI, Waist-hip ratio, FPG, 30 m PG, 2 h PG, HbA1C | No major complication | All at 12 months follow-up |
Huang 2011 [35] | Hyperlipidemia, hypertension, steatohepatitis, gouty arthritis | 0 | 90.9% (20/22) at 12 months. | 0 | BMI, Glucose, HbA1, ctriglyceride | No state | All at 12 months follow-up |
Lee 2011 [36] | No state | 0 | 0%,11%, 37%, 53%, 57%, and 55% patients in 1, 4, 12, 26, and 52 weeks and 2 years | 0 | BMI, Glucose, insulin, HbA1c, HOMA, Glucose, Insulin, Insulinogenic index | seven minor complications, no major complication | 62 at 1,4 week, 45 at 12 week, 40 at 26 weeks, 30 at 52 weeks, 20 at 2 years. |
Shah 2010 [37] | Hypertension, dyslipidemia | 0 | 80% (12/15)at 3 months | 0 | BMI, Waist circumference, Fasting blood glucose, HbA1c | No major complication | All at 6, 9 months |
Lee 2008 [38] | 2 comorbidity | 0 | 76.5% (34/44) at 1 year | 0 | BMI, glucose, T-chole, Triglyceride, insulin, CP, HbA1c | No major complication | At 1 year |